Issue 6-7/2013

  • Rules unlock access to Orphan drugs

    In this issue:

    Putting a fair price-tag on orphan drugs

    After more than two years of negotiations, a collaboration involving Member States, the European Commission, patient representative organisations, national insurers and industry has finally published the first non-binding guidelines for evaluating and reimbursing orphan drugs. The framework is a first tentative step forward in addressing a thorny and divisive topic. How much should pharma companies be allowed to earn for treating rare diseases? And how much can insurers afford to pay?

    Volume 2015

    Volume 2014

    Volume 2013

    Volume 2012

    © 2007-2015 BIOCOM


    Alle Kurse


    • NORDIC NANOVECTOR (N)24.00 NOK23.71%
    • TRANSGENE (F)4.72 EUR23.56%
    • BAVARIAN NORDIC (D)41.03 EUR20.85%


    • THROMBOGENICS (B)3.09 EUR-20.97%
    • ZELTIA (E)3.35 EUR-12.76%
    • OXFORD BIOMEDICA (UK)8.00 GBP-12.09%


    • KARO BIO (S)38.50 SEK2336.7%
    • TRANSGENE (F)4.72 EUR65.6%
    • BIOTECH PHARMACON (N)12.50 NOK32.0%


    • THROMBOGENICS (B)3.09 EUR-39.3%
    • BIONOR PHARMA (N)1.26 NOK-38.2%
    • WILEX (D)2.05 EUR-37.5%


    • KARO BIO (S)38.50 SEK4595.1%
    • ADOCIA (F)87.65 EUR438.1%
    • GALAPAGOS (B)54.02 EUR329.4%


    • CHRONTECH PHARMA (S)0.01 SEK-85.7%
    • BIOTEST (D)19.84 EUR-76.1%
    • NEOVACS (F)0.89 EUR-74.7%

    No liability assumed, Date: 28.08.2015